BACKGROUND: Endogenous sex hormone levels have been associated with increased breast cancer risk in postmenopausal women in several prospective studies. However, it remains unclear to what extent serum hormone-breast cancer associations differ with receptor status. METHODS: Associations between serum sex hormone levels and breast cancer risk were assessed in a nested case-control study on postmenopausal women of the ORDET cohort. After a median follow-up of 13.5 years, 165 women developed breast cancer. Relative risks of developing breast cancer were estimated by conditional logistic regression. RESULTS: Total and free testosterone levels were directly associated with breast cancer risk [relative risk, 3.28 (95% confidence interval, 1.93-5.55) and 2.86 (95% confidence interval, 1.66-4.94), respectively, for highest versus lowest quartile]. When relations between hormone level and risk of breast cancer expressing various receptor combinations were assessed, high total testosterone was significantly associated with increased risk of estrogen receptor-positive cancers, irrespective of progesterone receptor status. High total testosterone was also associated with increased risk of both human epidermal growth factor receptor 2 (HER2)-negative (HER2(-)) and HER2(+) cancers. High estradiol tended to be associated with increased risk of HER2(-) cancer and inversely associated with HER2(+) cancer, with significant (P = 0.027) heterogeneity between HER2(+) and HER2(-) cancers. However, there were relatively few HER2(+) cases. CONCLUSIONS: This study provides further evidence that high levels of circulating testosterone increase the risk of developing breast cancer in postmenopausal women. The cancers that develop are mainly estrogen receptor positive. Although HER2(+) and HER2(-) breast cancers were both associated with high total testosterone, they showed opposing associations with estrogen.
BACKGROUND: Endogenous sex hormone levels have been associated with increased breast cancer risk in postmenopausal women in several prospective studies. However, it remains unclear to what extent serum hormone-breast cancer associations differ with receptor status. METHODS: Associations between serum sex hormone levels and breast cancer risk were assessed in a nested case-control study on postmenopausal women of the ORDET cohort. After a median follow-up of 13.5 years, 165 women developed breast cancer. Relative risks of developing breast cancer were estimated by conditional logistic regression. RESULTS: Total and free testosterone levels were directly associated with breast cancer risk [relative risk, 3.28 (95% confidence interval, 1.93-5.55) and 2.86 (95% confidence interval, 1.66-4.94), respectively, for highest versus lowest quartile]. When relations between hormone level and risk of breast cancer expressing various receptor combinations were assessed, high total testosterone was significantly associated with increased risk of estrogen receptor-positive cancers, irrespective of progesterone receptor status. High total testosterone was also associated with increased risk of both human epidermal growth factor receptor 2 (HER2)-negative (HER2(-)) and HER2(+) cancers. High estradiol tended to be associated with increased risk of HER2(-) cancer and inversely associated with HER2(+) cancer, with significant (P = 0.027) heterogeneity between HER2(+) and HER2(-) cancers. However, there were relatively few HER2(+) cases. CONCLUSIONS: This study provides further evidence that high levels of circulating testosterone increase the risk of developing breast cancer in postmenopausal women. The cancers that develop are mainly estrogen receptor positive. Although HER2(+) and HER2(-) breast cancers were both associated with high total testosterone, they showed opposing associations with estrogen.
Authors: J Feng; L Li; N Zhang; J Liu; L Zhang; H Gao; G Wang; Y Li; Y Zhang; X Li; D Liu; J Lu; B Huang Journal: Oncogene Date: 2016-11-28 Impact factor: 9.867
Authors: Kerstin L Edlefsen; Rebecca D Jackson; Ross L Prentice; Imke Janssen; Aleksandar Rajkovic; Mary Jo O'Sullivan; Garnet Anderson Journal: Menopause Date: 2010 May-Jun Impact factor: 2.953
Authors: Niki L Dimou; Nikos Papadimitriou; Dipender Gill; Sofia Christakoudi; Neil Murphy; Marc J Gunter; Ruth C Travis; Tim J Key; Renee T Fortner; Philip C Haycock; Sarah J Lewis; Kenneth Muir; Richard M Martin; Konstantinos K Tsilidis Journal: Int J Epidemiol Date: 2019-06-01 Impact factor: 7.196
Authors: Kristin L Campbell; Karen E Foster-Schubert; Catherine M Alfano; Chia-Chi Wang; Ching-Yun Wang; Catherine R Duggan; Caitlin Mason; Ikuyo Imayama; Angela Kong; Liren Xiao; Carolyn E Bain; George L Blackburn; Frank Z Stanczyk; Anne McTiernan Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Annekatrin Lukanova; Helja-Marja Surcel; Eva Lundin; Marjo Kaasila; Hans-Ake Lakso; Helena Schock; Anika Husing; Rudolf Kaaks; Pentti Koskela; Kjell Grankvist; Eero Pukkala; Anne Zeleniuch-Jacquotte; Matti Lehtinen; Paolo Toniolo Journal: Int J Cancer Date: 2011-05-09 Impact factor: 7.396
Authors: Ghada N Farhat; Neeta Parimi; Rowan T Chlebowski; Joann E Manson; Garnet Anderson; Alison J Huang; Eric Vittinghoff; Jennifer S Lee; Andrea Z Lacroix; Jane A Cauley; Rebecca Jackson; Deborah Grady; Dorothy S Lane; Lawrence Phillips; Michael S Simon; Steven R Cummings Journal: J Natl Cancer Inst Date: 2013-09-16 Impact factor: 13.506
Authors: Christy G Woolcott; Yurii B Shvetsov; Frank Z Stanczyk; Lynne R Wilkens; Kami K White; Christian Caberto; Brian E Henderson; Loïc Le Marchand; Laurence N Kolonel; Marc T Goodman Journal: Endocr Relat Cancer Date: 2010-02-18 Impact factor: 5.678
Authors: Xuehong Zhang; Shelley S Tworoger; A Heather Eliassen; Susan E Hankinson Journal: Breast Cancer Res Treat Date: 2013-01-03 Impact factor: 4.872